Marcia Cruz-Correa Highlights Positive Results of Podium-303 Clinical Trial
Marcia Cruz-Correa, Chief Medical Officer at PanOncology Trials, shared a post on LinkedIn:
“Very excited to have been part of the investigators who participated in Podium-303 clinical trial to evaluate the role of Retifanlimab for patients with locally advanced or metastatic anal squamous cell cancer.
The clinical trial demonstrated superior efficacy among patients who received the drug as compared to placebo with an improvement of 30 to 37% in disease control. We were able to see with our own eyes, the benefit in our patients from Puerto Rico, who were able to participate in this clinical trial.
We were most grateful to our patients, their families and and the investigators Dr. Omayra, Gonzalez and Dr. Josselyn Molina as well as our dedicated Research and Clinical staff PanOncology Trials
Congratulations to all investigators involved and to the Incyte team!.”
More posts featuring Marcia Cruz-Correa on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023